{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:27:24Z","timestamp":1790083644157,"version":"4.0.1"},"reference-count":98,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>Although maintenance immunosuppression with calcineurin inhibitors (CNIs) has greatly reduced rejection rates in renal transplant recipients, long-term use can contribute to eventual nephrotoxicity, potentially leading to allograft injury and loss. Several clinical trials have shown that, compared with CNIs, belatacept-based maintenance immunosuppression can improve renal function, reduce the incidence of de novo donor-specific antibodies, and improve long-term patient\/graft survival. However, the US Food and Drug Administration\u2013approved belatacept-based regimen is also associated with higher acute rejection (AR) rates than CNI-based immunosuppression. Recent data from clinical trials and real-world studies suggest that initial posttransplant treatment with CNI-based immunosuppression followed by conversion to a belatacept-based regimen can lower the AR risk while preserving patient and renal health. This review article summarizes the available data pertaining to belatacept treatment protocols, with a focus on conversion to belatacept. Also discussed are studies of protocol modifications intended to further mitigate AR risks and belatacept-related outcomes in special populations, such as patients receiving marginal kidneys and those at risk of new-onset diabetes. Overall, the available data suggest that conversion from CNI- to belatacept-based immunosuppression \u22656 mo posttransplant appears to be effective in lowering the AR risk compared with belatacept use in the de novo setting or conversion &lt;6 mo posttransplant. The addition of an extended transient or low-dose CNI treatment to de novo belatacept or a prolonged CNI taper in the conversion setting may also help lower the AR risk. However, additional studies will be needed to optimize the many variables applicable to belatacept treatment, particularly for different patient subgroups.<\/jats:p>","DOI":"10.1097\/tp.0000000000005506","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T04:00:28Z","timestamp":1756872028000},"page":"e302-e323","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Tailoring of Immunosuppression With Belatacept in De Novo and Conversion Settings and Risk Mitigation Strategies"],"prefix":"10.1097","volume":"110","author":[{"given":"Richard N.","family":"Formica","sequence":"first","affiliation":[{"name":"Department of Medicine, Section of Nephrology and Transplantation, Yale School of Medicine, New Haven, CT."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian P.","family":"Larsen","sequence":"additional","affiliation":[{"name":"Emory Transplant Center, Emory University, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Rostaing","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hemodialysis, Apheresis and Kidney Transplantation, Centre Hospitalier Universitaire Grenoble-Alpes, University Grenoble Alpes, Grenoble, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"R1-20260127","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/ajhp\/61.6.565","article-title":"Drug-related dyslipidemia after renal transplantation.","volume":"61","author":"Mathis","year":"2004","journal-title":"Am J Health Syst Pharm"},{"key":"R2-20260127","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1432-2277.2008.00640.x","article-title":"Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation.","volume":"21","author":"Roland","year":"2008","journal-title":"Transpl Int"},{"key":"R3-20260127","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/j.1600-6143.2007.01749.x","article-title":"Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus.","volume":"2007","author":"Vincenti","year":"2007","journal-title":"Am J Transplant"},{"key":"R4-20260127","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM198409133111103","article-title":"Cyclosporine-associated chronic nephropathy.","volume":"311","author":"Myers","year":"1984","journal-title":"N Engl J Med"},{"key":"R5-20260127","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1432-2277.2000.tb01004.x","article-title":"Neurotoxicity of calcineurin inhibitors: impact and clinical management.","volume":"13","author":"Bechstein","year":"2000","journal-title":"Transpl Int"},{"key":"R6-20260127","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1016\/S0041-1345(02)03606-0","article-title":"Tacrolimus-induced neurotoxicity in kidney transplant recipients.","volume":"34","author":"Veroux","year":"2002","journal-title":"Transplant Proc"},{"key":"R7-20260127","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJM198605153142005","article-title":"Renal histopathologic alterations in patients treated with cyclosporine for uveitis.","volume":"314","author":"Palestine","year":"1986","journal-title":"N Engl J Med"},{"key":"R8-20260127","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00000478-199301000-00007","article-title":"The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine.","volume":"17","author":"Randhawa","year":"1993","journal-title":"Am J Surg Pathol"},{"key":"R9-20260127","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.1990.03450010067032","article-title":"Kidney transplantation under FK 506.","volume":"264","author":"Starzl","year":"1990","journal-title":"JAMA"},{"key":"R10-20260127","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1056\/NEJMoa020009","article-title":"The natural history of chronic allograft nephropathy.","volume":"349","author":"Nankivell","year":"2003","journal-title":"N Engl J Med"},{"key":"R11-20260127","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/tri.12413","article-title":"Cardiovascular morbidity and mortality after kidney transplantation.","volume":"28","author":"Stoumpos","year":"2015","journal-title":"Transpl Int"},{"key":"R12-20260127","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1600-6143.2005.00749.x","article-title":"Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.","volume":"5","author":"Larsen","year":"2005","journal-title":"Am J Transplant"},{"key":"R15-20260127","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"key":"R16-20260127","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant"},{"key":"R17-20260127","first-page":"CD010699","article-title":"Belatacept for kidney transplant recipients.","volume":"2014","author":"Masson","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R18-20260127","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation.","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med"},{"key":"R19-20260127","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1111\/ajt.13830","article-title":"Long-term outcomes in belatacept- versus cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study.","volume":"16","author":"Durrbach","year":"2016","journal-title":"Am J Transplant"},{"key":"R20-20260127","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/ajt.14721","article-title":"De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.","volume":"18","author":"Bray","year":"2018","journal-title":"Am J Transplant"},{"key":"R21-20260127","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/TP.0b013e3182007b95","article-title":"An integrated safety profile analysis of belatacept in kidney transplant recipients.","volume":"90","author":"Griny\u00f3","year":"2010","journal-title":"Transplantation"},{"key":"R22-20260127","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1016\/j.transproceed.2016.05.017","article-title":"Risk evaluation and outcome of pneumocystis jirovecii pneumonia in kidney transplant patients.","volume":"48","author":"Brakemeier","year":"2016","journal-title":"Transplant Proc"},{"key":"R23-20260127","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/ndt\/gfz255","article-title":"Opportunistic infections after conversion to belatacept in kidney transplantation.","volume":"35","author":"Bertrand","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"R24-20260127","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/ajt.16132","article-title":"CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept.","volume":"21","author":"Karadkhele","year":"2021","journal-title":"Am J Transplant"},{"key":"R25-20260127","doi-asserted-by":"crossref","first-page":"5159","DOI":"10.3390\/jcm10215159","article-title":"Belatacept use after kidney transplantation and its effects on risk of infection and COVID-19 vaccine response.","volume":"10","author":"Terrec","year":"2021","journal-title":"J Clin Med"},{"key":"R26-20260127","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/cid\/ciab474","article-title":"Genetic and epidemiologic analyses of an outbreak of pneumocystis jirovecii pneumonia among kidney transplant recipients in the United States.","volume":"74","author":"Azar","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R27-20260127","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/15269248221122894","article-title":"Overall infectious complications related to belatacept conversion in comparison to tacrolimus in kidney transplant recipients.","volume":"32","author":"Marvin","year":"2022","journal-title":"Prog Transplant"},{"key":"R28-20260127","doi-asserted-by":"crossref","first-page":"e13983","DOI":"10.1111\/tid.13983","article-title":"Impact of belatacept and tacrolimus on cytomegalovirus viral load control and relapse in moderate and high-risk cytomegalovirus serostatus kidney transplant recipients.","volume":"24","author":"Magua","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"R29-20260127","doi-asserted-by":"crossref","first-page":"101857","DOI":"10.1016\/j.trim.2023.101857","article-title":"Increased CMV disease and \u201csevere\u201d BK viremia with belatacept vs. sirolimus three-drug maintenance immunosuppression.","volume":"79","author":"Petrossian","year":"2023","journal-title":"Transpl Immunol"},{"key":"R30-20260127","doi-asserted-by":"crossref","first-page":"ofae158","DOI":"10.1093\/ofid\/ofae158","article-title":"An unexpectedly high incidence of invasive fungal diseases in solid organ transplant recipients taking belatacept for organ rejection prophylaxis: a single-center retrospective cohort study.","volume":"11","author":"Bell","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"R31-20260127","doi-asserted-by":"crossref","first-page":"e14318","DOI":"10.1111\/tid.14318","article-title":"Evolving trends in immunosuppression use and cytomegalovirus infection risk over the past decade in kidney transplantation.","volume":"26","author":"Soliman","year":"2024","journal-title":"Transpl Infect Dis"},{"key":"R32-20260127","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-6143.2011.03785.x","article-title":"Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.","volume":"12","author":"Vincenti","year":"2012","journal-title":"Am J Transplant"},{"key":"R33-20260127","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1600-6143.2011.03914.x","article-title":"Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys.","volume":"12","author":"Pestana","year":"2012","journal-title":"Am J Transplant"},{"key":"R34-20260127","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1111\/ajt.12459","article-title":"Long-term exposure to belatacept in recipients of extended criteria donor kidneys.","volume":"13","author":"Charpentier","year":"2013","journal-title":"Am J Transplant"},{"key":"R35-20260127","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/ajt.13886","article-title":"Efficacy and safety outcomes of extended criteria donor kidneys by subtype: subgroup analysis of BENEFIT-EXT at 7 years after transplant.","volume":"17","author":"Florman","year":"2017","journal-title":"Am J Transplant"},{"key":"R36-20260127","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1600-6143.2010.03338.x","article-title":"Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients.","volume":"11","author":"Ferguson","year":"2011","journal-title":"Am J Transplant"},{"key":"R37-20260127","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/ajt.12712","article-title":"Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors.","volume":"14","author":"Kirk","year":"2014","journal-title":"Am J Transplant"},{"key":"R38-20260127","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1111\/ajt.16121","article-title":"Kidney transplantation using alemtuzumab, belatacept, and sirolimus: five-year follow-up.","volume":"20","author":"Schmitz","year":"2020","journal-title":"Am J Transplant"},{"key":"R39-20260127","doi-asserted-by":"crossref","first-page":"e1419","DOI":"10.1097\/TXD.0000000000001419","article-title":"Treatment of de novo renal transplant recipients with calcineurin inhibitor-free, belatacept plus everolimus-based immunosuppression.","volume":"9","author":"Peddi","year":"2023","journal-title":"Transplant Direct"},{"key":"R40-20260127","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1111\/ajt.14353","article-title":"Belatacept combined with transient calcineurin inhibitor therapy prevents rejection and promotes improved long-term renal allograft function.","volume":"17","author":"Adams","year":"2017","journal-title":"Am J Transplant"},{"key":"R41-20260127","doi-asserted-by":"crossref","first-page":"101834","DOI":"10.1016\/j.trim.2023.101834","article-title":"Belatacept-based immunosuppression in practice: a single center experience.","volume":"78","author":"Ortiz","year":"2023","journal-title":"Transpl Immunol"},{"key":"R42-20260127","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/ajt.15688","article-title":"Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: a prospective, randomized multicenter trial.","volume":"20","author":"Woodle","year":"2020","journal-title":"Am J Transplant"},{"key":"R43-20260127","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.2215\/CJN.13100820","article-title":"Belatacept for simultaneous calcineurin inhibitor and chronic corticosteroid immunosuppression avoidance: two-year results of a prospective, randomized multicenter trial.","volume":"16","author":"Kaufman","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"R44-20260127","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2215\/CJN.05840710","article-title":"Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.","volume":"6","author":"Rostaing","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R45-20260127","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1432-2277.2012.01535.x","article-title":"Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study.","volume":"25","author":"Grinyo","year":"2012","journal-title":"Transpl Int"},{"key":"R46-20260127","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1053\/j.ajkd.2016.09.021","article-title":"Safety and efficacy outcomes 3 years after switching to belatacept from a calcineurin inhibitor in kidney transplant recipients: results from a phase 2 randomized trial.","volume":"69","author":"Griny\u00f3","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"R47-20260127","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1681\/ASN.2021050628","article-title":"Conversion from calcineurin inhibitor- to belatacept-based maintenance immunosuppression in renal transplant recipients: a randomized phase 3b trial.","volume":"32","author":"Budde","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"R48-20260127","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2215\/CJN.0000000000000411","article-title":"Long-term outcomes after conversion to a belatacept-based immunosuppression in kidney transplant recipients.","volume":"19","author":"Divard","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"R49-20260127","doi-asserted-by":"crossref","first-page":"100574","DOI":"10.1016\/j.xkme.2022.100574","article-title":"Cardiovascular risk following conversion to belatacept from a calcineurin inhibitor in kidney transplant recipients: a randomized clinical trial.","volume":"5","author":"Bredewold","year":"2022","journal-title":"Kidney Med"},{"key":"R50-20260127","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1097\/TP.0000000000002192","article-title":"Conversion to belatacept in maintenance kidney transplant patients: a retrospective multicenter European study.","volume":"102","author":"Darres","year":"2018","journal-title":"Transplantation"},{"key":"R51-20260127","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/ndt\/gfac178","article-title":"Belatacept rescue conversion in kidney transplant recipients with vascular lesions (Banff cv score >2): a retrospective cohort study.","volume":"38","author":"Bertrand","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"R52-20260127","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/ckj\/sfy115","article-title":"Conversion from tacrolimus to belatacept improves renal function in kidney transplant patients with chronic vascular lesions in allograft biopsy.","volume":"12","author":"P\u00e9rez-S\u00e1ez","year":"2018","journal-title":"Clin Kidney J"},{"key":"R53-20260127","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/tri.12822","article-title":"Experience with belatacept rescue therapy in kidney transplant recipients.","volume":"29","author":"Brakemeier","year":"2016","journal-title":"Transpl Int"},{"key":"R54-20260127","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.transproceed.2017.05.013","article-title":"Late conversion to belatacept after kidney transplantation: outcome and prognostic factors.","volume":"49","author":"Durr","year":"2017","journal-title":"Transplant Proc"},{"key":"R55-20260127","doi-asserted-by":"crossref","first-page":"101737","DOI":"10.1016\/j.trim.2022.101737","article-title":"Conversion to belatacept in kidney transplant recipients with chronic antibody-mediated rejection (CAMR).","volume":"76","author":"Moein","year":"2023","journal-title":"Transpl Immunol"},{"key":"R56-20260127","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s12882-020-01992-6","article-title":"Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.","volume":"21","author":"Choi","year":"2020","journal-title":"BMC Nephrol"},{"key":"R57-20260127","doi-asserted-by":"crossref","first-page":"1968029","DOI":"10.1155\/2018\/1968029","article-title":"Pilot analysis of late conversion to belatacept in kidney transplant recipients for biopsy-proven chronic tacrolimus toxicity.","volume":"2018","author":"Gupta","year":"2018","journal-title":"J Transplant"},{"key":"R58-20260127","doi-asserted-by":"crossref","first-page":"10228","DOI":"10.3389\/ti.2022.10228","article-title":"Three-year outcomes in kidney transplant recipients switched from calcineurin inhibitor-based regimens to belatacept as a rescue therapy.","volume":"35","author":"Morel","year":"2022","journal-title":"Transpl Int"},{"key":"R59-20260127","doi-asserted-by":"crossref","first-page":"e13823","DOI":"10.1111\/ctr.13823","article-title":"Conversion to belatacept within 1-year of renal transplantation in a diverse cohort including patients with donor-specific antibodies.","volume":"34","author":"Santeusanio","year":"2020","journal-title":"Clin Transplant"},{"key":"R60-20260127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ctr.12930","article-title":"Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients.","volume":"31","author":"Wojciechowski","year":"2017","journal-title":"Clin Transplant"},{"key":"R61-20260127","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1111\/ajt.13698","article-title":"Effect of an early switch to belatacept among calcineurin inhibitor-intolerant graft recipients of kidneys from extended-criteria donors.","volume":"16","author":"Le Meur","year":"2016","journal-title":"Am J Transplant"},{"key":"R62-20260127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ctr.12951","article-title":"Early conversion to belatacept after renal transplantation.","volume":"31","author":"Nair","year":"2017","journal-title":"Clin Transplant"},{"key":"R63-20260127","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1111\/ajt.13322","article-title":"Safe conversion from tacrolimus to belatacept in high immunologic risk kidney transplant recipients with allograft dysfunction.","volume":"15","author":"Gupta","year":"2015","journal-title":"Am J Transplant"},{"key":"R64-20260127","doi-asserted-by":"crossref","first-page":"101882","DOI":"10.1016\/j.trim.2023.101882","article-title":"Early conversion to belatacept-based immunosuppression regimen promotes improved long-term renal graft function in kidney transplant recipients.","volume":"80","author":"Moein","year":"2023","journal-title":"Transpl Immunol"},{"key":"R65-20260127","doi-asserted-by":"crossref","first-page":"e0240335","DOI":"10.1371\/journal.pone.0240335","article-title":"Prevention of acute rejection after rescue with belatacept by association of low-dose tacrolimus maintenance in medically complex kidney transplant recipients with early or late graft dysfunction.","volume":"15","author":"Gallo","year":"2020","journal-title":"PLoS One"},{"key":"R66-20260127","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/TP.0000000000001985","article-title":"Early conversion to belatacept in kidney transplant recipients with low glomerular filtration rate.","volume":"102","author":"Abdelwahab Elhamahmi","year":"2018","journal-title":"Transplantation"},{"key":"R67-20260127","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.transproceed.2020.11.001","article-title":"Belatacept conversion protocols and outcomes in kidney transplant recipients.","volume":"53","author":"Yazdi","year":"2021","journal-title":"Transplant Proc"},{"key":"R68-20260127","doi-asserted-by":"crossref","first-page":"101207","DOI":"10.1016\/j.trim.2019.04.002","article-title":"Switching renal transplant recipients to belatacept therapy: results of a real-life gradual conversion protocol.","volume":"56","author":"Malvezzi","year":"2019","journal-title":"Transpl Immunol"},{"key":"R69-20260127","doi-asserted-by":"crossref","first-page":"102050","DOI":"10.1016\/j.trim.2024.102050","article-title":"Belatacept based immunosuppression: what and when to combine?","volume":"85","author":"Schilsky","year":"2024","journal-title":"Transpl Immunol"},{"key":"R70-20260127","doi-asserted-by":"crossref","first-page":"1096881","DOI":"10.3389\/fimmu.2022.1096881","article-title":"Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients.","volume":"13","author":"Tawhari","year":"2022","journal-title":"Front Immunol"},{"issue":"suppl_1","key":"R71-20260127","doi-asserted-by":"crossref","first-page":"gfae069-0994-1327","DOI":"10.1093\/ndt\/gfae069.994","article-title":"#1327 mTOR inhibitors in kidney transplant recipients: long-term efficacy and discontinuation causes.","volume":"39","author":"Cassia","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"R72-20260127","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/ajt.15229","article-title":"Belatacept in renal transplant recipient with mild immunologic risk factor: a pilot prospective study (BELACOR).","volume":"19","author":"Leibler","year":"2019","journal-title":"Am J Transplant"},{"key":"R73-20260127","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/B978-0-323-52978-5.00040-9","article-title":"Infection in renal transplant recipients.","author":"Sawinski","year":"2019","journal-title":"Chronic Kid Dis Dial Transplant"},{"key":"R74-20260127","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.trre.2016.12.001","article-title":"Epstein-Barr virus and renal transplantation.","volume":"31","author":"Le","year":"2017","journal-title":"Transplant Rev (Orlando)"},{"key":"R75-20260127","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.3390\/jcm13082217","article-title":"JC virus in kidney transplant population: are we cautious enough?","volume":"13","author":"Pjanic","year":"2024","journal-title":"J Clin Med"},{"key":"R76-20260127","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.3390\/jcm9113479","article-title":"Opportunistic infections and efficacy following conversion to belatacept-based therapy after kidney transplantation: a French multicenter cohort.","volume":"9","author":"Bertrand","year":"2020","journal-title":"J Clin Med"},{"key":"R77-20260127","first-page":"801","article-title":"Infection in patients on belatacept regimen after kidney transplant.","volume":"21","author":"Moein","year":"2023","journal-title":"Exp Clin Transplant"},{"key":"R78-20260127","doi-asserted-by":"crossref","first-page":"e14298","DOI":"10.1111\/tid.14298","article-title":"Belatacept-based immunosuppression does not confer increased risk of BK polyomavirus-DNAemia relative to tacrolimus-based immunosuppression.","volume":"26","author":"Eichenberger","year":"2024","journal-title":"Transpl Infect Dis"},{"issue":"suppl 3","key":"R79-20260127","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients.","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"R80-20260127","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12882-017-0553-2","article-title":"Renal association clinical practice guideline in post-operative care in the kidney transplant recipient.","volume":"18","author":"Baker","year":"2017","journal-title":"BMC Nephrol"},{"key":"R81-20260127","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/clpt.2012.84","article-title":"Time-varying belatacept exposure and its relationship to efficacy\/safety responses in kidney-transplant recipients.","volume":"92","author":"Zhou","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R82-20260127","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1111\/ajt.13853","article-title":"Comparison of utilization and clinical outcomes for belatacept- and tacrolimus-based immunosuppression in renal transplant recipients.","volume":"16","author":"Wen","year":"2016","journal-title":"Am J Transplant"},{"key":"R83-20260127","doi-asserted-by":"crossref","first-page":"e13531","DOI":"10.1111\/ctr.13531","article-title":"Alemtuzumab induction and belatacept maintenance in marginal pathology renal allografts.","volume":"33","author":"Sparkes","year":"2019","journal-title":"Clin Transplant"},{"key":"R84-20260127","doi-asserted-by":"crossref","first-page":"e1615","DOI":"10.1097\/TXD.0000000000001615","article-title":"Use of a belatacept-based Immunosuppression for kidney transplantation from donors after circulatory death: a paired kidney analysis.","volume":"10","author":"Eid","year":"2024","journal-title":"Transplant Direct"},{"key":"R85-20260127","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/nep.14106","article-title":"Outcomes of de novo belatacept-based immunosuppression regimen and avoidance of calcineurin inhibitors in recipients of kidney allografts at higher risk for underutilization.","volume":"27","author":"Patel","year":"2022","journal-title":"Nephrology (Carlton)"},{"key":"R86-20260127","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/TP.0b013e31820c10eb","article-title":"Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies).","volume":"91","author":"Vanrenterghem","year":"2011","journal-title":"Transplantation"},{"key":"R87-20260127","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.2215\/CJN.00270111","article-title":"Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes.","volume":"6","author":"Rostaing","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R88-20260127","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1097\/TXD.0000000000000964","article-title":"Late conversion from calcineurin inhibitors to belatacept in kidney-transplant recipients has a significant beneficial impact on glycemic parameters.","volume":"6","author":"Terrec","year":"2019","journal-title":"Transplant Direct"},{"key":"R89-20260127","doi-asserted-by":"crossref","first-page":"e14041","DOI":"10.1111\/ctr.14041","article-title":"Conversion to belatacept maintenance immunosuppression in HIV-positive kidney transplant recipients.","volume":"34","author":"Santeusanio","year":"2020","journal-title":"Clin Transplant"},{"key":"R90-20260127","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1093\/ckj\/sfaa231","article-title":"Belatacept-based immunosuppressive regimen in HIV-positive kidney transplant recipients.","volume":"14","author":"El Sakhawi","year":"2020","journal-title":"Clin Kidney J"},{"key":"R91-20260127","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jaad.2019.09.070","article-title":"Belatacept reduces skin cancer risk in kidney transplant recipients.","volume":"82","author":"Wang","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R92-20260127","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jaad.2024.05.068","article-title":"De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy.","volume":"91","author":"Jew","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"R93-20260127","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0140-6736(05)17962-8","article-title":"New-onset diabetes after transplantation: a threat to graft and patient survival.","volume":"365","author":"Krentz","year":"2005","journal-title":"Lancet"},{"key":"R94-20260127","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1097\/TXD.0000000000000767","article-title":"Improved glucose tolerance in a kidney transplant recipient with type 2 diabetes mellitus after switching from tacrolimus to belatacept: a case report and review of potential mechanisms.","volume":"4","author":"de Graav","year":"2018","journal-title":"Transplant Direct"},{"key":"R95-20260127","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3390\/jcm13030793","article-title":"Diabetic kidney disease in post-kidney transplant patients.","volume":"13","author":"Pham","year":"2024","journal-title":"J Clin Med"},{"key":"R96-20260127","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1097\/TP.0000000000003485","article-title":"Kidney transplantation in HIV-positive patients: current practice and management strategies.","volume":"105","author":"Muller","year":"2021","journal-title":"Transplantation"},{"key":"R97-20260127","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.ajkd.2018.02.352","article-title":"Kidney transplantation in HIV-positive patients: a single-center, 16-year experience.","volume":"73","author":"Malat","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"R98-20260127","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.12688\/f1000research.10414.1","article-title":"Impact of antiretroviral therapy on clinical outcomes in HIV+ kidney transplant recipients: review of 58 cases.","volume":"5","author":"Rosa","year":"2016","journal-title":"F1000Res"},{"key":"R99-20260127","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1111\/ajt.14382","article-title":"Skin cancers in organ transplant recipients.","volume":"17","author":"Mittal","year":"2017","journal-title":"Am J Transplant"},{"key":"R100-20260127","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nature08996","article-title":"Opposing roles for calcineurin and ATF3 in squamous skin cancer.","volume":"465","author":"Wu","year":"2010","journal-title":"Nature"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T11:00:53Z","timestamp":1769511653000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":98,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005506","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]}}}